Stock Detail
RESPONSE GENETICS INC
Biotechnology
RGDX @ Yahoo Finance | RGDX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.70 | $1.70 | $0.07 | 4.29% | 0.00 | $1.63 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.63 | $1.63 | 12,069 | 33.21M | 4,020 | -11.33 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.75 | 1.73 | 1.68 | 1.66 | 1.61 |
Stock Profile
Response Genetics, Inc. engages in the research and development of pharmacogenomic diagnostic tests for the treatment of cancer. It offers customizable menu of fee-based pharmacogenomics services, which support clinical trials that identify patient biomarkers. The company also provides comprehensive reports on relative gene expression calculations from RT-PCR reactions using its validated database. In addition, Response Genetics conducts research for various academic institutions, including the University of Southern California. It has a collaboration agreement with Roche Diagnostics to develop new assays to test for key biomarkers. The company was founded in 1999. It was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in 2000. Response Genetics is based in Los Angeles, California.